Vγ9Vδ2 TCR NFAT-Luciferase Rep

γδ TCRs (T cell receptors), αβ TCRs, and antibodies, result from gene rearrangements and offer the immune system the possibility to recognize several different types of antigens. γδ TCRs recognize antigens in a similar way to antibodies, being able to recognize full protein antigens and being independent on antigen binding to the MHC (major histocompatibility complex). Examples of such antigens include pyrophosphomonoesters and E. Coli, or glycoprotein I from Herpes simplex. γδ TCRs are cell type specific, with Vγ9Vδ2 being present in T cells and corresponding to about 5% of the T cell population in blood.  Vγ9Vδ2 T cells are involved mostly in immune responses to pathogens and long-term modulation of inflammation, and can recognize non-peptide phosphor-antigens, alkylamines and synthetic aminobisphosphonates. Vγ9Vδ2 T cells are being studied for the treatment of solid tumors and hematological disorders and are becoming a highly promising cancer therapy. Further studies on how best to utilize Vγ9Vδ2 T cells, and methods to enhance their presence, will open new therapeutic avenues for cancer and infections.